TY  - JOUR
A1  - Jaschke, Alexander
A1  - Chung, Bomee
A1  - Hesse, Deike
A1  - Kluge, Reinhart
A1  - Zahn, Claudia
A1  - Moser, Markus
A1  - Petzke, Klaus-Jürgen
A1  - Brigelius-Flohé, Regina
A1  - Puchkov, Dmytro
A1  - Koepsell, Hermann
A1  - Heeren, Joerg
A1  - Joost, Hans-Georg
A1  - Schürmann, Annette
T1  - The GTPase ARFRP1 controls the lipidation of chylomicrons in the Golgi of the intestinal epithelium
JF  - Human Molecular Genetics
N2  - The uptake and processing of dietary lipids by the small intestine is a multistep process that involves several steps including vesicular and protein transport. The GTPase ADP-ribosylation factor-related protein 1 (ARFRP1) controls the ARF-like 1 (ARL1)-mediated Golgi recruitment of GRIP domain proteins which in turn bind several Rab-GTPases. Here, we describe the essential role of ARFRP1 and its interaction with Rab2 in the assembly and lipidation of chylomicrons in the intestinal epithelium. Mice lacking Arfrp1 specifically in the intestine \((Arfrp1^{vil−/−})\) exhibit an early post-natal growth retardation with reduced plasma triacylglycerol and free fatty acid concentrations. \(Arfrp1^{vil−/−}\) enterocytes as well as Arfrp1 mRNA depleted Caco-2 cells absorbed fatty acids normally but secreted chylomicrons with a markedly reduced triacylglycerol content. In addition, the release of apolipoprotein A-I (ApoA-I) was dramatically decreased, and ApoA-I accumulated in the \(Arfrp1^{vil−/−}\) epithelium, where it predominantly co-localized with Rab2. The release of chylomicrons from Caco-2 was markedly reduced after the suppression of Rab2, ARL1 and Golgin-245. Thus, the GTPase ARFRP1 and its downstream proteins are required for the lipidation of chylo­microns and the assembly of ApoA-I to these particles in the Golgi of intestinal epithelial cells.
KW  - ARF
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125658
VL  - 21
IS  - 14
ER  - 
TY  - JOUR
A1  - Guth, Sabine
A1  - Hüser, Stephanie
A1  - Roth, Angelika
A1  - Degen, Gisela
A1  - Diel, Patrick
A1  - Edlund, Karolina
A1  - Eisenbrand, Gerhard
A1  - Engel, Karl-Heinz
A1  - Epe, Bernd
A1  - Grune, Tilman
A1  - Heinz, Volker
A1  - Henle, Thomas
A1  - Humpf, Hans-Ulrich
A1  - Jäger, Henry
A1  - Joost, Hans-Georg
A1  - Kulling, Sabine E.
A1  - Lampen, Alfonso
A1  - Mally, Angela
A1  - Marchan, Rosemarie
A1  - Marko, Doris
A1  - Mühle, Eva
A1  - Nitsche, Michael A.
A1  - Röhrdanz, Elke
A1  - Stadler, Richard
A1  - van Thriel, Christoph
A1  - Vieths, Stefan
A1  - Vogel, Rudi F.
A1  - Wascher, Edmund
A1  - Watzl, Carsten
A1  - Nöthlings, Ute
A1  - Hengstler, Jan G.
T1  - Contribution to the ongoing discussion on fluoride toxicity
JF  - Archives of Toxicology
N2  - Since the addition of fluoride to drinking water in the 1940s, there have been frequent and sometimes heated discussions regarding its benefits and risks. In a recently published review, we addressed the question if current exposure levels in Europe represent a risk to human health. This review was discussed in an editorial asking why we did not calculate benchmark doses (BMD) of fluoride neurotoxicity for humans. Here, we address the question, why it is problematic to calculate BMDs based on the currently available data. Briefly, the conclusions of the available studies are not homogeneous, reporting negative as well as positive results; moreover, the positive studies lack control of confounding factors such as the influence of well-known neurotoxicants. We also discuss the limitations of several further epidemiological studies that did not meet the inclusion criteria of our review. Finally, it is important to not only focus on epidemiological studies. Rather, risk analysis should consider all available data, including epidemiological, animal, as well as in vitro studies. Despite remaining uncertainties, the totality of evidence does not support the notion that fluoride should be considered a human developmental neurotoxicant at current exposure levels in European countries.
KW  - pharmacology/toxicology
KW  - occupational medicine/industrial medicine
KW  - environmental health
KW  - biomedicine, general
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-307161
SN  - 0340-5761
SN  - 1432-0738
VL  - 95
IS  - 7
ER  -